Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Thrombocytopenia 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Rituximab 154Cyclophosphamide 116fludarabine phosphate 109fludarabine 68Mycophenolic Acid 62Whole-Body Irradiation 56ibrutinib 46Tacrolimus 46Peripheral Blood Stem Cell Transplantation 44Lenalidomide 43Cyclosporine 36Busulfan 35Bendamustine Hydrochloride 34Antilymphocyte Serum 31ofatumumab 30obinutuzumab 28Melphalan 28idelalisib 26Alemtuzumab 26Filgrastim 25Methotrexate 23venetoclax 22Chlorambucil 21Granulocyte Colony-Stimulating Factor 20acalabrutinib 19thymoglobulin 18Cyclosporins 16Sirolimus 15Etoposide 15Pentostatin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Lymphocytic, Chronic, B-Cell × Interleukin-11 × Clear all
NCT00012298 2018-08-09

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
81 enrolled 16 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡